Literature DB >> 19401607

Neurologic complications of HIV disease and their treatment.

Scott L Letendre1, Ronald J Ellis, Ivan Everall, Beau Ances, Ajay Bharti, J Allen McCutchan.   

Abstract

Substantial work on the peripheral and central nervous system complications of HIV was presented at the 16th Conference on Retroviruses and Opportunistic Infections. Six studies of more than 4500 volunteers identified that distal sensory polyneuropathy remains common, ranging from 19% to 66%, with variation based on disease stage, type of antiretroviral therapy, age, and height. Eight studies of more than 2500 volunteers identified that neurocognitive disorders are also common, ranging from 25% to 69%, with variation based on stage of disease, antiretroviral use, diabetes mellitus, and coinfection with hepatitis viruses. Therapy-focused studies identified that resistance testing of cerebrospinal fluid (CSF)-derived HIV may improve management of people with HIV-associated neurologic complications, that poorly penetrating antiretroviral therapy is associated with persistent low-level HIV RNA in CSF, and that efavirenz concentrations in CSF are low but in the therapeutic range in most individuals. Neuroimaging reports identified that people living with HIV had abnormal findings on magnetic resonance imaging (gray matter atrophy, abnormal white matter), magnetic resonance spectroscopy (lower neuronal metabolites), and blood-oxygen-level dependent functional magnetic resonance imaging (lower cerebral blood flow). Other important findings on the basic neuroscience of HIV and diagnosis and management of neurologic opportunistic infections are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401607      PMCID: PMC3065886     

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  16 in total

1.  Molecular clock of viral evolution, and the neutral theory.

Authors:  T Gojobori; E N Moriyama; M Kimura
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center.

Authors:  R K Heaton; I Grant; N Butters; D A White; D Kirson; J H Atkinson; J A McCutchan; M J Taylor; M D Kelly; R J Ellis
Journal:  J Int Neuropsychol Soc       Date:  1995-05       Impact factor: 2.892

4.  Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Authors:  Andrea Antinori; Carlo Federico Perno; Maria Letizia Giancola; Federica Forbici; Giuseppe Ippolito; Richard M Hoetelmans; Stephen C Piscitelli
Journal:  Clin Infect Dis       Date:  2005-11-10       Impact factor: 9.079

5.  Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.

Authors:  K T Tashima; A M Caliendo; M Ahmad; J M Gormley; W D Fiske; J M Brennan; T P Flanigan
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

6.  Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline.

Authors:  Paul M Thompson; Rebecca A Dutton; Kiralee M Hayashi; Arthur W Toga; Oscar L Lopez; Howard J Aizenstein; James T Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-14       Impact factor: 11.205

7.  Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS.

Authors:  Marco Salemi; Susanna L Lamers; Stephanie Yu; T de Oliveira; Walter M Fitch; Michael S McGrath
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Molecular clock-like evolution of human immunodeficiency virus type 1.

Authors:  Yi Liu; David C Nickle; Daniel Shriner; Mark A Jensen; Gerald H Learn; John E Mittler; James I Mullins
Journal:  Virology       Date:  2004-11-10       Impact factor: 3.616

9.  Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

Authors:  Patrick R Harrington; Gretja Schnell; Scott L Letendre; Kimberly Ritola; Kevin Robertson; Colin Hall; Christina L Burch; Cassandra B Jabara; Dominic T Moore; Ronald J Ellis; Richard W Price; Ronald Swanstrom
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

10.  Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

Authors:  Nicky Longley; Conrad Muzoora; Kabanda Taseera; James Mwesigye; Joselyne Rwebembera; Ali Chakera; Emma Wall; Irene Andia; Shabbar Jaffar; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

View more
  33 in total

1.  Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles.

Authors:  Supriya D Mahajan; Indrajit Roy; Gaixia Xu; Ken-Tye Yong; Hong Ding; Ravikumar Aalinkeel; Jessica Reynolds; Donald Sykes; Bindukumar B Nair; Elaine Y Lin; Paras N Prasad; Stanley A Schwartz
Journal:  Curr HIV Res       Date:  2010-07       Impact factor: 1.581

Review 2.  Towards nanomedicines for neuroAIDS.

Authors:  Vidya Sagar; Sudheesh Pilakka-Kanthikeel; Ravi Pottathil; Shailendra K Saxena; Madhavan Nair
Journal:  Rev Med Virol       Date:  2014-01-07       Impact factor: 6.989

3.  The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals.

Authors:  Laurie M Baker; Robert H Paul; Jodi M Heaps-Woodruff; Jee Yoon Chang; Mario Ortega; Zachary Margolin; Christina Usher; Brian Basco; Sarah Cooley; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

4.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.

Authors:  Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

5.  Neural dysregulation during a working memory task in human immunodeficiency virus-seropositive and hepatitis C coinfected individuals.

Authors:  J Z K Caldwell; A Gongvatana; B A Navia; L H Sweet; K Tashima; M Ding; R A Cohen
Journal:  J Neurovirol       Date:  2014-05-28       Impact factor: 2.643

6.  Methamphetamine and HIV-1 Tat down regulate β-catenin signaling: implications for methampetamine abuse and HIV-1 co-morbidity.

Authors:  Amit Sharma; Xiu-Ti Hu; T Celeste Napier; Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-09       Impact factor: 4.147

Review 7.  Th17, gut, and HIV: therapeutic implications.

Authors:  Peter W Hunt
Journal:  Curr Opin HIV AIDS       Date:  2010-03       Impact factor: 4.283

8.  Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.

Authors:  Michelle Kiebala; Oksana Polesskaya; Zhenqiang Yao; Seth W Perry; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

Review 9.  Neurologic presentations of AIDS.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah Commins; Andrew Levine
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

10.  Brain viral burden, neuroinflammation and neurodegeneration in HAART-treated HIV positive injecting drug users.

Authors:  Donald B Smith; Peter Simmonds; Jeanne E Bell
Journal:  J Neurovirol       Date:  2014-01-14       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.